Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Filed Nov 6, 2023 · 10-Q · 37 days after period end · 0000950170-23-059391
| Metric | Q3 2023 | Q3 2020 | Q3 2019 |
|---|---|---|---|
| Revenue | $0.00 | $12.66M | $12.51M |
| Net Income | -$108.43M | -$27.22M | -$12.82M |
| EPS Diluted | -$0.99 | -$0.42 | -$6.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 6, 2023 · 37 d after period end
